# GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection

> **NCT01209078** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 84 (actual)

## Conditions studied

- Skin Infections, Bacterial

## Interventions

- **DRUG:** GSK1322322
- **DRUG:** Linezolid
- **DRUG:** GSK1322322 placebo
- **DRUG:** Linezolid placebo

## Key facts

- **NCT ID:** NCT01209078
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-17
- **Primary completion:** 2011-01-18
- **Final completion:** 2011-01-18
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2017-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01209078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01209078, "GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01209078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*